Mon Apr 27 18:25:26 SGT 2015  
SINGAPORE
SEXUALHEALTH™
    Genital Warts
SINGAPORE SEXUALHEALTH™
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment
28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing

Genital Warts | SINGAPORE SEXUALHEALTH™

Summary

Genital Warts | SINGAPORE SEXUALHEALTH™ @singaporesexualhealth_com: Genital warts, Singapore. Private & confidential service.

Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
SHIM CLINIC
SINGAPORE SEXUALHEALTH™
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital Warts | SINGAPORE SEXUALHEALTH™
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Description

Table of Contents

Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.

References

Warts - on male sex organ Genital warts appear within 3 months after sexual contact with an infected person.

Genital warts:

  • are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
  • may also be hard and smooth
  • occur alone or in groups
  • tend to recur after treatment
  • increase the risk of cervical cancer in women.


Warts - on female sex organ An infected woman may infect her newborn during childbirth.

A person with genital warts can infect others through sexual contact.



Genital warts treatment / HPV treatment

HPV / human papillomavirus.

  • 120 known human papillomavirus (HPV)
  • 51 HPV types, and 3 subtypes are genital HPV as they infect the genital mucosa.
  • 31 genital HPV types are low risk
  • 6 genital HPV types are intermediate risk
  • 17 genital HPV types are high risk
They cause Genital HPV types, cancer risk, vaccine and test coverage
Type
Species
Risk
Cervarix
Gardasil
Gardasil-9
DigeneHR
DigenePS
CobasHPV
Digene
HybriBio
PapilloCheck
InnoLiPA
LinearArray
61 3 L ----------+-
72 3 L ----------+-
81 3 L -------+--+-
83 3 L ----------+-
84 3 L ----------+-
62 3 L ----------+-
CP6108 3 L ----------+-
71 15 L ---------++-
26 5 H ---------++-
51 5 H ---+-++++++-
69 5 H ---------++-
82 5 H --------+++-
IS39 5 H ----------+-
18 7 H +++++++++++-
39 7 H ---+-++++++-
45 7 H --+++++++++-
59 7 H ---+-++++++-
68 7 H ---+-++++++-
70 7 H --------+++-
53 6 H -------++++-
56 6 H ---+-++++++-
66 6 H -----+-++++-
54 13 L ---------++-
42 1 L ------+++-+-
40 8 L --------+++-
43 8 L ------++++--
6 10 L -++---+++++-
11 10 L -++---+++++-
44 10 L ------++++--
74 10 L ---------+--
16 9 H +++++++++++-
31 9 H --++-++++++-
33 9 H --++-++++++-
35 9 H ---+-++++++-
52 9 H --++-++++++-
58 9 H --++-++++++-
67 9 H ----------+-
73 11 H --------+++-

Legend: 71 (CP 8061), 73/MM9, 81 (CP 8304), 82 (MM4), 82 (IS 39), 83 (MM7), 84 (MM8), 89 (CP 6108)

References

Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types:
  • Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
  • V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs

Vaccine Against Disease Age D
o
s
e
s
Dose schedule Price
per
dose
(SG$)
Havrix™ 1440 Adult Hepatitis A virus Hepatitis A ≥19y 2 m 0 & 6-12 $90/=
Twinrix® Hepatitis A virus
Hepatitis B virus
Hepatitis A
Hepatitis B
1-15y 2 m 0, 6-12 $135/=
≥16y 3 m 0, 1, 6
4 d 0, 7, 21 & m 12
Inactivated / Fractional / Protein / Subunit / Recombinant
Engerix™-B 20 μg Hepatitis B virus Hepatitis B 11-15y 2 m 0, & 6 $50/=
≥20y 3 m 0, 1, & 6
4 m 0, 1, 2, & 12 or
d 0, 7, 21 & m 12
Gardasil® HPV
types 6, 11, 16, & 18
Genital warts
Cervical cancer
9-26y 3 m 0, 2, & 6 or
m 0, 1, & 4
$195/=
Cervarix® HPV
types 16, & 18
(31, 33, & 45)
10-25y 3 m 0, 1, & 6
m 0, 1, & 5
m 0, 2½, 12
$195/=
V503 HPV
types 6, 11, 16, 18,
31, 33, 45,
52, & 58
3 m 0, 2, & 6 or
m 0, 1, & 4
$???/=

HPV test for men/women.

  • Digene® High-Risk HPV DNA Test
  • Digene® HPV DNA Test
  • Digene® HPV Genotyping PS Test
  • Hybribio®
    • HPV GenoArray Test Kit
    • Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
    • Able to differentiate which types are positive.
    • May be available in Singapore soon.
  • Cobas® HPV Test
    • Cobas® HPV Test
    • Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
    • The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
    • Cost is SG$200/=
  • LINEAR ARRAY® HPV Genotyping Test
    • LINEAR ARRAY® HPV Genotyping Test
    • Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
  • INNO-LiPA HPV Genotyping Extra
    • INNO-LiPA HPV Genotyping Extra
    • Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
  • PapilloCheck®
    • PapilloCheck®
    • Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
Contraception (females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing.
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception (females only)
2 weeks HIV DNA PCR test
1 month 20 minute HIV rapid test - SD Bioline HIV Ag/Ab Combo:
- Fingerprick blood sampling.
3 months 20 minute HIV rapid test - OraQuick®:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.

References


Latest News

Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high‐risk types of human papillomavirus
Sat, 25 Apr 2015 03:15:20 +0100 | Journal of Medical Virology
In conclusion, Roche Cobas HPV, RFMP HPV PapilloTyper, and HC2 showed high agreement rates. Roche Cobas HPV and RFMP HPV PapilloTyper are particularly useful, since both provide HPV specific genotypes, HPV16 and HPV18. (Source: Journal of Medical Virology)

Prevalence of genital dysplasia after kidney transplantation – a retrospective, non‐interventional study from two centers
Sat, 25 Apr 2015 00:00:00 +0100 | Acta Obstetricia et Gynecologica Scandinavica
ConclusionsFemale RT patients have an increased risk for the development of genital dysplasia in general and of cervical dysplasia in particular. Within this cohort, women at a young age at the time of transplantation and after re‐transplantation are at highest risk for the development of genital dysplasia.This article is protected by copyright. All rights reserved. (Source: Acta Obstetricia et Gynecologica Scandinavica)

MiR-34a Inhibits Viability and Invasion of Human Papillomavirus–Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin
Fri, 24 Apr 2015 08:46:27 +0100 | International Journal of Gynecological Cancer
Conclusions: This study confirmed a novel miR-34a–E2F3–survivin axis in the tumor suppressor role of miR-34a in cervical cancer. (Source: International Journal of Gynecological Cancer)

Women who received HPV vaccine may need another shot
Fri, 24 Apr 2015 00:16:11 +0100 | Health News: CBSNews.com
A newly approved vaccine protects against five additional high-risk strains of the human papillomavirus (Source: Health News: CBSNews.com)

Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia
Fri, 24 Apr 2015 00:00:00 +0100 | Journal of Medical Virology
This study reports for the first time the detection of adenine/thymine‐clustered hypermutation in the E2 gene of HPV16 isolated from clinical specimens with low‐ and high‐grade CIN lesions (CIN1/3). Differential DNA denaturation PCR, which utilizes lower denaturation temperatures to selectively amplify adenine/thymine‐rich DNA, identified clusters of adenine/thymine mutations in the E2 gene in 4 of 11 CIN1 (36.4%), and 6 of 27 CIN3 (22.2%) samples. Interestingly, the number of mutations per sample was higher in CIN3 than in CIN1. Although the relevance of E2 hypermutation in cervical carcinogenesis remains unclear, the observed hypermutation patterns strongly imply involvement of APOBEC3 proteins in editing the HPV16 genome during natural viral infection. J. Med. Virol. 9999: XX–...

Cures and curcumin -- turmeric offers potential therapy for oral cancers
Thu, 23 Apr 2015 04:00:00 +0100 | EurekAlert! - Cancer
(ecancermedicalscience) Curcumin, an antioxidant found in the common spice turmeric, has been found to limit the activity of human papillomavirus in oral cancer cells. (Source: EurekAlert! - Cancer)

Self-reported Oral Health, Oral Hygiene, and Oral HPV Infection in At-Risk Women in Ho Chi Minh City, Vietnam
Thu, 23 Apr 2015 00:00:00 +0100 | Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
This study aimed to examine the relationship between self-reported oral health, oral hygiene practices, and oral human papillomavirus (HPV) infection among women at risk for sexually transmitted infections in Ho Chi Minh City, Vietnam. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)

N‐Benzylcinnamide induces apoptosis in HPV16 and HPV18 cervical cancer cells via suppression of E6 and E7 protein expression
Thu, 23 Apr 2015 00:00:00 +0100 | IUBMB Life
Abstract

Efficacy of poly-gamma-glutamic acid in women with high-risk human papillomavirus-positive vaginal intraepithelial neoplasia: an observational pilot study.
Thu, 23 Apr 2015 00:00:00 +0100 | Journal of Microbiology and Biotechnology
Authors: Koo YJ, Min KJ, Hong JH, Lee JK

New 9-valent HPV vaccine is efficacious, well tolerated
Wed, 22 Apr 2015 18:50:03 +0100 | Skin and Allergy News
CHICAGO – The 9-valent human papillomavirus (HPV) vaccine recently approved by the Food and Drug Administration has high efficacy for preventing disease caused by the vaccine-covered viral types and is well tolerated, according to end-of study data from a randomized trial.